UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

CS1, a Potential New Therapeutic Antibody Target for the Treatment of Multiple Myeloma

Clinical cancer research, 2008-05, Vol.14 (9), p.2775-2784

2008

Volltextzugriff (PDF)

Combinatorial efficacy of anti-CS1 monoclonal antibody elotuzumab (HuLuc63) and bortezomib against multiple myeloma

Molecular cancer therapeutics, 2009-09, Vol.8 (9), p.2616-2624

2009

Volltextzugriff (PDF)

Germ Line Deletion of the CD1 Locus Exacerbates Diabetes in the NOD Mouse

Proceedings of the National Academy of Sciences - PNAS, 2001-06, Vol.98 (12), p.6777-6782

2001

Volltextzugriff (PDF)

Effect of Elotuzumab on Circulating Lymphocytes, Chemokines, and Cytokines In Multiple Myeloma Patients

Blood, 2010-11, Vol.116 (21), p.4070-4070

2010

Volltextzugriff (PDF)

Elotuzumab enhances natural killer cell activation and myeloma cell killing through interleukin-2 and TNF-α pathways

Cancer Immunology, Immunotherapy, 2015-01, Vol.64 (1), p.61-73

2015

Volltextzugriff (PDF)

CCR2 and CCR5 chemokine receptors differentially influence the development of autoimmune diabetes in the NOD mouse

Autoimmunity (Chur, Switzerland), 2010-03, Vol.43 (2), p.156-163

2010

Volltextzugriff (PDF)

The Paradoxical Effects of Interleukin 10 in the Immunoregulation of Autoimmune Diabetes

Journal of autoimmunity, 1996-04, Vol.9 (2), p.283-286

1996

Volltextzugriff (PDF)

Natural killer (NK) cell activation, cytokine production, and cytotoxicity in human PBMC/myeloma cell co-culture exposed to elotuzumab (Elo) alone or in combination with lenalidomide (Len)

Journal of clinical oncology, 2012-05, Vol.30 (15_suppl), p.8087-8087

2012

Volltextzugriff (PDF)

The CD25-binding antibody Daclizumab High-Yield Process has a distinct glycosylation pattern and reduced antibody-dependent cell-mediated cytotoxicity in comparison to Zenapax

mAbs, 2016-10, Vol.8 (7), p.1417-1424

2016

Volltextzugriff (PDF)

Elotuzumab enhances natural killer cell activation and myeloma cell killing through interleukin-2 and TNF-[alpha] pathways

Cancer immunology, immunotherapy, 2015-01, Vol.64 (1), p.61

2015

Volltextzugriff (PDF)

CD40 ligand-CD40 interactions are necessary for the initiation of insulitis and diabetes in nonobese diabetic mice

The Journal of immunology (1950), 1997-11, Vol.159 (9), p.4620-4627

1997

Volltextzugriff (PDF)

Coxsackieviral-mediated diabetes: induction requires antigen-presenting cells and is accompanied by phagocytosis of beta cells

Clinical immunology (Orlando, Fla.), 2004-02, Vol.110 (2), p.134-144

2004

Volltextzugriff (PDF)

Elotuzumab (HuLuc63) Activates CD56dim Natural Killer Cells and Monocytes Resulting in the Release of IP-10 and MCP-1

Blood, 2008-11, Vol.112 (11), p.108-108

2008

Volltextzugriff (PDF)

CS-1 Is Expressed in Nasal Type NK/T Cell Lymphomas and Angioimmunoblastic T-Cell Lymphomas: Implications for Targeted Therapy with Elotuzumab (HuLuc63)

Blood, 2008-11, Vol.112 (11), p.1779-1779

2008

Volltextzugriff (PDF)

Interferon gamma (IFN-gamma) is necessary for the genesis of acetylcholine receptor-induced clinical experimental autoimmune myasthenia gravis in mice

The Journal of experimental medicine, 1997-08, Vol.186 (3), p.385-391

1997

Volltextzugriff (PDF)

Pancreatic IL-4 Expression Results in Islet-Reactive Th2 Cells That Inhibit Diabetogenic Lymphocytes in the Nonobese Diabetic Mouse

The Journal of immunology (1950), 1999-08, Vol.163 (3), p.1696-1703

1999

Volltextzugriff (PDF)

A Mechanism for IL-10-Mediated Diabetes in the Nonobese Diabetic (NOD) Mouse: ICAM-1 Deficiency Blocks Accelerated Diabetes

The Journal of immunology (1950), 2000-12, Vol.165 (12), p.7330-7337

2000

Volltextzugriff (PDF)

The Th2 Cytokine IL-4 Is Not Required for the Progression of Antibody-Dependent Autoimmune Myasthenia Gravis

The Journal of immunology (1950), 1998-09, Vol.161 (6), p.2856-2862

1998

Volltextzugriff (PDF)

The Microbial Product Lipopolysaccharide Confers Diabetogenic Potential on the T Cell Repertoire of BDC2.5/NOD Mice: Implications for the Etiology of Autoimmune Diabetes

Clinical immunology (Orlando, Fla.), 2000-05, Vol.95 (2), p.93-98

2000

Volltextzugriff (PDF)

CS1: A Potential New Therapeutic Target for the Treatment of Multiple Myeloma

Blood, 2006-11, Vol.108 (11), p.3457-3457

2006

Volltextzugriff (PDF)

CS1 Is Expressed on Myeloma Cells from Early Stage, Late Stage, and Drug-Treated Multiple Myeloma Patients, and Is Selectively Targeted by the HuLuc63 Antibody

Blood, 2006-11, Vol.108 (11), p.660-660

2006

Volltextzugriff (PDF)

Islet-Specific Expression of IL-10 Promotes Diabetes in Nonobese Diabetic Mice Independent of Fas, Perforin, TNF Receptor-1, and TNF Receptor-2 Molecules

The Journal of immunology (1950), 2000-09, Vol.165 (5), p.2841-2849

2000

Volltextzugriff (PDF)

Vaccination with Glutamic Acid Decarboxylase Plasmid DNA Protects Mice from Spontaneous Autoimmune Diabetes and B7/CD28 Costimulation Circumvents That Protection

Clinical immunology (Orlando, Fla.), 2001-05, Vol.99 (2), p.241-252

2001

Volltextzugriff (PDF)

IL-10 Impacts Autoimmune Diabetes Via a CD8+ T Cell Pathway Circumventing the Requirement for CD4+ T and B Lymphocytes

The Journal of immunology (1950), 1998-10, Vol.161 (8), p.4420-4427

1998

Volltextzugriff (PDF)

IL-10 Deficiency Does Not Inhibit Insulitis and Accelerates Cyclophosphamide-Induced Diabetes in the Nonobese Diabetic Mouse

Cellular immunology, 2000-06, Vol.202 (2), p.97-102

2000

Volltextzugriff (PDF)

1 – 25 von 36

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(31)
Mit Volltextzugriff
(32)

Publikationsform

Sprache

Englisch
(36)

Erscheinungsjahr

n.n

Thema

Science & Technology
(26)
Life Sciences & Biomedicine
(25)
Immunology
(24)
Animals
(23)
Mice
(21)
Diabetes Mellitus, Type 1 - Immunology
(13)
Female
(13)
Mice, Inbred Nod
(11)
Mice, Scid
(8)
Mice, Transgenic
(8)
Humans
(7)
Islets Of Langerhans - Pathology
(7)
Islets Of Langerhans - Immunology
(6)
Mice, Inbred C57bl
(6)
Mice, Knockout
(6)
Aids/hiv
(5)
Diabetes Mellitus, Type 1 - Genetics
(5)
Diabetes Mellitus, Type 1 - Pathology
(5)
Lymphocyte Activation
(5)
T-Lymphocytes - Immunology
(5)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

CS1, a Potential New Therapeutic Antibody Target for the Treatment of Multiple Myeloma

Combinatorial efficacy of anti-CS1 monoclonal antibody elotuzumab (HuLuc63) and bortezomib against multiple myeloma

Germ Line Deletion of the CD1 Locus Exacerbates Diabetes in the NOD Mouse

Effect of Elotuzumab on Circulating Lymphocytes, Chemokines, and Cytokines In Multiple Myeloma Patients

Elotuzumab enhances natural killer cell activation and myeloma cell killing through interleukin-2 and TNF-α pathways

CCR2 and CCR5 chemokine receptors differentially influence the development of autoimmune diabetes in the NOD mouse

The Paradoxical Effects of Interleukin 10 in the Immunoregulation of Autoimmune Diabetes

Natural killer (NK) cell activation, cytokine production, and cytotoxicity in human PBMC/myeloma cell co-culture exposed to elotuzumab (Elo) alone or in combination with lenalidomide (Len)

The CD25-binding antibody Daclizumab High-Yield Process has a distinct glycosylation pattern and reduced antibody-dependent cell-mediated cytotoxicity in comparison to Zenapax

Elotuzumab enhances natural killer cell activation and myeloma cell killing through interleukin-2 and TNF-[alpha] pathways

CD40 ligand-CD40 interactions are necessary for the initiation of insulitis and diabetes in nonobese diabetic mice

Coxsackieviral-mediated diabetes: induction requires antigen-presenting cells and is accompanied by phagocytosis of beta cells

Elotuzumab (HuLuc63) Activates CD56dim Natural Killer Cells and Monocytes Resulting in the Release of IP-10 and MCP-1

CS-1 Is Expressed in Nasal Type NK/T Cell Lymphomas and Angioimmunoblastic T-Cell Lymphomas: Implications for Targeted Therapy with Elotuzumab (HuLuc63)

Interferon gamma (IFN-gamma) is necessary for the genesis of acetylcholine receptor-induced clinical experimental autoimmune myasthenia gravis in mice

Pancreatic IL-4 Expression Results in Islet-Reactive Th2 Cells That Inhibit Diabetogenic Lymphocytes in the Nonobese Diabetic Mouse

A Mechanism for IL-10-Mediated Diabetes in the Nonobese Diabetic (NOD) Mouse: ICAM-1 Deficiency Blocks Accelerated Diabetes

The Th2 Cytokine IL-4 Is Not Required for the Progression of Antibody-Dependent Autoimmune Myasthenia Gravis

The Microbial Product Lipopolysaccharide Confers Diabetogenic Potential on the T Cell Repertoire of BDC2.5/NOD Mice: Implications for the Etiology of Autoimmune Diabetes

CS1: A Potential New Therapeutic Target for the Treatment of Multiple Myeloma

CS1 Is Expressed on Myeloma Cells from Early Stage, Late Stage, and Drug-Treated Multiple Myeloma Patients, and Is Selectively Targeted by the HuLuc63 Antibody

Islet-Specific Expression of IL-10 Promotes Diabetes in Nonobese Diabetic Mice Independent of Fas, Perforin, TNF Receptor-1, and TNF Receptor-2 Molecules

Vaccination with Glutamic Acid Decarboxylase Plasmid DNA Protects Mice from Spontaneous Autoimmune Diabetes and B7/CD28 Costimulation Circumvents That Protection

IL-10 Impacts Autoimmune Diabetes Via a CD8+ T Cell Pathway Circumventing the Requirement for CD4+ T and B Lymphocytes

IL-10 Deficiency Does Not Inhibit Insulitis and Accelerates Cyclophosphamide-Induced Diabetes in the Nonobese Diabetic Mouse

Suchergebnisse filtern